Drug Target Review Podcast

Drug Target Review
  • 0.0 (0)
  • SCIENCE
  • MONTHLY
Drug Target Review Podcast Podcast

Podcast by Drug Target Review

  1. 17 SEPT

    Scaling genetic medicine with tRNA

    In this episode, we will discuss the unique biology of tRNA and how it can be leveraged to scale the development of genetic medicines.  This conversation features Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, and Caroline Köhrer, Vice President, Discovery Platform at Alltrna.

    14 min

  2. 19 AUG

    Combatting disease with antibody drug conjugates

    In this podcast episode, we will be investigating the key considerations in selecting an antibody for use in antibody drug conjugates (ADCs). Also, we will be discussing the preclinical models used to evaluate the pharmacokinetics and pharmacodynamics of ADCs.  This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.

    30 min

  3. 1 AUG

    Advanced techniques in toxicity testing

    In this episode, we explore advanced toxicity testing methods to enhance the predictivity and reliability of toxicity assessments. This conversation features Professor Ruth Roberts, co-director and co-founder at ApconiX and Dr Oksana Sirenko, Senior Scientist at Molecular Devices.

    28 min

  4. 25 JUL

    How mRNA technology could revolutionise therapeutics

    In this podcast episode, we will be discussing how mRNA vaccines for cancer treatment engage with the immune system to illicit an anti-tumour response, how they could synergise with other cancer treatments, as well as which cancers show most promise for this approach. This conversation features Dr Rebecca Boohaker, Director of Oncology at Southern Research, and Fusataka Koide, Senior Director of Business Development at Southern Research.

    32 min

  5. 13 JUN

    Small molecules for regenerative medicine

    In this podcast episode, we will be discussing how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy, focusing on degenerative muscle diseases. This conversation features Frank Gleeson, CEO and co-founder of Satellos, and Dr Michael Rudnicki, co-founder and Chief Discovery Officer at Satellos.

    20 min

  6. 8 MAY

    Exploring the wonders of molecular biology

    Bringing their expertise, we are thrilled to introduce Dr Matthew Nelson, Vice President, Genetics and Genomics, Deerfield Discovery and Development and CEO at Genscience and Dr Jake Rubens, President of Quotient Therapeutics and Origination Partner at Flagship Pioneering. Key discussion points: DNA has been called the code of life. How much of this code have we deciphered? How is technology evolving to allow us to better understand the consequences of genetic changes (DNA mutations, epigenetics, etc.) and health and disease? What impact do we expect this to have in drug discovery? How do we go from sequencing the DNA of individuals to making connections to health and disease? What are some examples of gene-disease links we’ve made that have informed drug target selection? This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.

    25 min

  7. 29 APR

    Investigating the promising future of organoids

    In this podcast episode, titled ‘Investigating the promising future of organoids’, we will be discussing the ways in which organoids are being used to study diseases and improve drug development. We explore the specific preclinical models organoids are replacing, the current limitations of organoids and how to overcome these, as well as where the field is heading.  This conversation features Dr Radhika Menon, Senior Scientist of Neurobiology at Ncardia, Dr Etienne De Braekeleer, Senior Research Scientist at AstraZeneca, and Dr Paige Vinson, Director of High Throughput Screening at Southern Research.

    55 min

  8. 2 APR

    Breaking resistance – the future of immunotherapy in oncology

    In this podcast episode titled 'Breaking resistance - the future of immunotherapy in oncology' we will be discussing checkpoint inhibitors in cancer therapy, and how primary and secondary treatment resistance are still limiting their clinical success in a variety of cancer types. In this episode, we want to explore the current status and potential solutions to addressing this major hurdle in oncology. This conversation features Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, and Roy Baynes, Chief Scientific Officer at Eikon Therapeutics.

    26 min
See All (35)

About

Podcast by Drug Target Review

Information

  • Creator
    Drug Target Review
  • Years Active
    2021 - 2024
  • Episodes
    35
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    Drug Target Review Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada